Hope Rugo· @hoperugo · X·· 2 天前评分90
正文 · 机器翻译
@myesmo #ESMO26。令人激动人心的会议正式开始了——今天将进行前两场BC口头报告。第一场会议包括Natalee的OS数据、延长letrozole治疗在B42中的长期获益,以及3种新型ADCs在HER2 low/HR+ & Talent中的巨大获益。@OncoAlert
872 浏览 · 16 赞 · 6 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgOpening ceremony at #ESMO26 #ESMO26 #ESMOAmbassadors #ESMOcommunity @myESMO在 X 查看被引用的帖子
来源:Hope Rugo · x.com
